US Pharm. 2009;34(5):36-38.Mylan Inc. settled all patent litigation relating to desloratadine tablets 5 mg, the generic version of Schering-Plough's Clarinex allergy medication. This litigation has been pending in the U.S. District Court of New Jersey since September 2006. Pursuant to the settlement, Mylan will have the right to market desloratadine tablets 5 mg in the U.S. on July 1, 2012, or earlier in certain circumstances, provided that the FDA approves Mylan's abbreviated new drug application. Mylan's product may be the prescription form or an OTC version, depending on the status of Clarinex at the time.